Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons (Q84122212)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 01 January 2009

Language	Label	Description	Also known as
English	Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons	scientific article published on 01 January 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

based on heuristic

inferred from title

author name string

Thomas Elter

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Barbara F Eichhorst

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Clemens-Martin Wendtner

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Current hematologic malignancy reports

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

43-46

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20425437%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of Residual Disease in B-Cell Chronic Lymphocytic Leukemia Patients in Clinical and Bone-Marrow Remission Using CD5-CD19 Markers and PCR Study of Gene Rearrangements

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection of minimal residual disease in B Chronic Lymphocytic Leukemia (CLL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20425437

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84122212&oldid=2222920090"